期刊文献+

塞克硝唑阴道泡腾片人体药代动力学研究 被引量:2

Study of pharmacokinetics of secnidazole vagina effervescent tablets in healthy volunteers
下载PDF
导出
摘要 目的:研究塞克硝唑阴道泡腾片人体内的药代动力学特征。方法:单次给药分别应用250、500、750 mg,多次给药应用500 mg,连用7 d,采用HPLC测定血浆中塞克硝唑的浓度。用DAS软件计算其药代动力学参数。结果:健康已婚女性受试者单次使用塞克硝唑阴道泡腾片250、5007、50 mg后的T1/2β分别为18.84、15.25、21.86 h,与文献报道基本一致;Tmax分别为12.22、14.00、18.00 h,Cmax分别为3.58、5.42、8.00 mg.L-1,AUC分别为103.52、190.992、96.92 mg.h-1.L-1,与口服制剂相比,吸收较慢,峰浓度较低,吸收量较少,提示本药全身作用较小,不良反应也较少,局部残留较多有利于发挥治疗作用。多次使用塞克硝唑500 mg后的T1/2β=22.74 h、Cmax=14.30 mg.L-1、Tmax=1 1.60 h、AUC=520.14 mg.h-1.L-1,Cmax和AUC与单次给药相比明显增大,说明该药因半衰期较长,长期用药有一定的蓄积,多次连续用药应引起注意。结论:本试验提供了塞克硝唑阴道泡腾片体内血药浓度的HPLC测定方法及药动学参数,为其临床应用和合理用药提供了参考和依据。 AIM: To study the phannacokinetics of secnidazole vagina effervescent tablets in healthy volunteers. METHODS: 250, 500 and 750 mg secnidazole vagina effervescent tablets were used in single-dose groups; 500 mg seenidazole vagina effervescent tablets were used for 7 days in multi-dose group. The concentrations of secnidazole in plasma were determined by HPLC. The parameters of pharmacokinetics were calculated by DAS software. RESULTS AND CONCLUSION: The pharmacokinetic parameters after administration of a single dose of secnidazole vagina effervescent tablets (250, 500, 750 mg) in health married female volunteers were as follows: Tlao were 18.84, 15.25, and 21.86 h, in accordance with the literatures; Tmax were 12.22, 14.00, and 18.00 h; Cmax were 3.58, 5.42, and 8.00 mg·L^-1; AUC were 103.52,190.99, and 296.92 mg·h^-1 ·L^-1 ,respectively. The absorption of secnidazole vagina effervescent tablets was slower and lower than oral tablets. The systemic actions and adverse reactions were fewer and rudimental concentrations were higher so as to show more local actions. The pharmacokinetic parameters after administration of multi doses of secnidazole vagina effervescent tablets (500 mg) were as follows: T1/2β = 22.74 h, Cmax= 14.30 mg·L^-1, Tmax = 11.60 h, and AUC = 520.14 mg· h^- 1· L^- 1. Cmax and AUC were higher than the results of a single dose. These showed that the drug can cumulate after a long-time administration because of its long half-life and required more caution.
出处 《中国临床药理学与治疗学》 CAS CSCD 2006年第1期66-69,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 塞克硝唑 泡腾片 药代动力学 血药浓度 高效液相色谱法 seenidazole effervescent tablets pharmaeokinetics plasma concentration high performance liquid ehromatography (HPLC)
  • 相关文献

参考文献5

  • 1戚燕,单慧军,吴松.反相高效液相色谱法测定塞克硝唑的含量及其有关物质[J].中国新药杂志,2002,11(4):294-296. 被引量:11
  • 2Gillis JC,Wiseman LR.Secnidazole-A review of its antimicrobial activity,pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis[J].Drug evaluation,1996;4:620-38
  • 3Saracoglu F,Gol K,Sahin I,Turkkani B,Aralay C,Oztopcu C.Treatment of bacterial vaginosis with oral or vaginal ornidazole,secnidazole and metronidazole[J].Int J Gynaecol Obstet,1998;1:59-61
  • 4Kenneth C.Lamp,Collin D.Freeman,Neil E,Klutman,Melinda K,Lacy.Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials[J].Clin Pharmacokinet,1999;5:353-73
  • 5Tenebaum H,Cuisinier FJG,Le Liboux A.Secnidazole concentrations in plasma and crevicular fluid after a single oral dose[J].J Clin Periodontol,1993;20:505-8

二级参考文献2

  • 1[1]Abdel Fattah M,Walily El,Abdine HH,et al. Spectrophotometric and HPLC determination of secnidazole in pharmaceutical tablets[J].J Pharm Biomed Anal,2000,22∶887-897.
  • 2[2]Sekhar KR,Naidu MUR,Sekhar EC,et al.Rapid and selective analysis of secnidazole in human plasma using high-performance liquid chromatography with ultraviolet detection[J].J Chromatogr B,1997,691∶208-211.

共引文献10

同被引文献11

  • 1Cimerman B,Camilo Coura LC,Salle JM,et al.Evaluation of secnidazole gel and tinidazole suspension in the treatment of giardiasis in children[J].Braz J Infect Dis,1997,1(5):241-245.
  • 2Di Prisco MC,Jimenez JC,Rodriguez N,et al.Clinical trial with secnidazole in a single dose in Venezuelan children infected by Giardia intestinalis[J].Invest Clin,2000,41(3):179-183.
  • 3Lamp KC,Freeman CD,Klutman NE,et al.Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials[J].Clin Pharmacokinet,1999,36(5):353-373.
  • 4Botero D.An overview of the clinical experience of secnidazole in giardiasis and amebiasis[J].Drug Invest,1994,8(Suppl 1):S47-S52.
  • 5Tenenbaum H,Cuisinier FJG,Le Liboux A,et al.Secnidazole concentrations in plasma and crevicular fluid after a single oral dose[J].J Clin Periodontol,1993,20:505-508.
  • 6Sobel JD.Management of vaginosis[J].Drug Invest,1994,8(Suppl 1):26-34.
  • 7Sawyer PR,Brogden RN,Pinder RM,et al.Tinidazole:a review of its antiprotozoal activity and therapeutic efficacy[J].Drugs,1976,11(6):423-440.
  • 8Bagnoli VR.An overview of the clinical experience with secnidazole in bacterial vaginosis and trichomoniasis[J].Drug Invest,1994,8(Suppl 1):S53-S60.
  • 9Bagnoli VR,Kesselring GL.Multicenter study,double blind,randomized comparative between secnidazole and tinidazole in the treatment of non-specific vaginitis[J].Rev Bras Med,1992,111(4):198-202.
  • 10潘靖文.塞克硝唑口服与外用联合治疗细菌性阴道炎的临床疗效观察[J].医学信息(中旬刊),2011,24(4):1513-1514. 被引量:1

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部